BeiGene to Webcast an Analyst and Investor Event from the American Society of Hematology Annual Meeting – NASDAQ (US) Website

BeiGene to Webcast an Analyst and Investor Event from the American Society of Hematology Annual Meeting

Dec 04, 2017 4:05 PM

CAMBRIDGE, Mass., and BEIJING, China, Dec. 04, 2017 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, today announced that the company will webcast an analyst and investor event being held at the 59th American Society of Hematology (ASH) Annual Meeting to discuss updated data and the development program for its BTK inhibitor zanubrutinib (BGB-3111). ASH will take place December 9-12, 2017 in Atlanta, GA.

Dial-in Information

Date & Time: Saturday, December 9, 2017, 8:00pm EST (Sunday, December 10, 2017, 9:00am China Standard Time)

Dial-In Numbers: 1-844-461-9930 or 1-478-219-0535 (US), 400-682-8609 or 800-870-0169 (China), 852-30114522 (Hong Kong), 65-66221010, 61-282239773, or 1-478-219-0535 (International)

Conference ID Number: 9086588

A live webcast and replay of the event will be available on BeiGene’s investor website, The dial-in replay will be available approximately two hours after the conference and will be available for two days following the event. It can be accessed by dialing 1-855-859-2056 or 1-404-537-3406 (US), 400-683-7185 (China), 852-30114541 (Hong Kong), 65-31583682, 61-282239792, or 1-855-859-2056 (International).

About BeiGene

BeiGene is a global, commercial-stage, research-based biotechnology company focused on molecularly targeted and immuno-oncology cancer therapeutics. With a team of over 700 employees in China, the United States, and Australia, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is also working to create combination solutions aimed to have both a meaningful and lasting impact on cancer patients. BeiGene markets ABRAXANE® (nanoparticle albumin–bound paclitaxel), REVLIMID® (lenalidomide), and VIDAZA® (azacitidine) in China under a license from Celgene Corporation.1

Investor/Media Contact

Lucy Li, Ph.D.
+1 781-801-1800


1 ABRAXANE®, REVLIMID®, and VIDAZA® are registered trademarks of Celgene Corporation.

Primary Logo

Source: BeiGene, LTD.